Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

EDL drugs

    • Home
    • EDL drugs
Policy / Regulatory

China’s NHC Sets Sights on Enhancing Grassroots Drug Management and Access

Fineline Cube Nov 25, 2024

The National Health Commission (NHC) has issued a set of opinions designed to accelerate the...

Policy / Regulatory

Shandong Releases Off-Label Drug Use Consensus, Expanding Clinical Guidance

Fineline Cube Aug 29, 2022

The Shandong Pharmaceutical Association (SPA) has released the “Shandong Province Expert Consensus on Off-label Drug...

Policy / Regulatory

NHSA Releases Draft Proposals for NRDL Annual Renewal Process

Fineline Cube Jun 14, 2022

The National Healthcare Security Administration (NHSA) has formulated and released draft proposals for rules covering...

Recent updates

  • Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion
  • Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer
  • Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal
  • Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen
  • Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Others

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.